Lipolytic C-terminal fragment.
HGH Fragment 176-191 (also "AOD-9604" in one development program) is the C-terminal 16-residue region of human growth hormone. Research interest focuses on its reported lipolytic activity in the absence of the growth-promoting effects of the parent hormone. Supplied as research-grade material with 3rd-party HPLC verification and full Certificate of Analysis per lot.
HGH Fragment 176-191 (also "AOD-9604" in one development program) is the C-terminal 16-residue region of human growth hormone. Research interest focuses on its reported lipolytic activity in the absence of the growth-promoting effects of the parent hormone.
Published studies describe the fragment as retaining the reported lipolytic and anti-lipogenic activity of full-length hGH while lacking activity at the growth hormone receptor or the IGF-1 axis. Reported mechanism involves beta-adrenergic receptor signaling and direct effects on adipocyte lipid metabolism.
Developed in the 1990s by Frank Ng's group at Monash (Australia). Tested clinically as AOD-9604 by Metabolic Pharmaceuticals for obesity (failed to meet primary endpoint in Phase IIb). Not FDA-approved; GRAS designation granted for cosmetic use.
The above summarizes published research literature. This is not medical advice, a protocol, or a recommendation for use. This compound is supplied for laboratory research only.
HGH Fragment 176-191 is a 16-residue peptide with molecular formula C78H125N23O23S2 and molecular weight of approximately 1,817.0 Da.
The full structural data and release specifications are in the Compound Profile section above. Every lot ships with an independently verified Certificate of Analysis.
Each lot is independently verified by a 3rd-party analytical laboratory (STERIS Labs, Alcami Analytical, or equivalent) before release. Release specification is HPLC purity ≥ 99.5% (typical > 99.8%), mass spectrometry identity match within ±0.5 Da, water content < 5.0% Karl Fischer, and endotoxin < 0.25 EU/mL by LAL (USP <85>).
Look up the full COA for your lot at coa-lookup.html.
All compounds ship at ambient temperature in discreet, tamper-evident packaging. Lyophilized peptide powder is stable at room temperature for typical transit windows, which is why research-grade vendors ship this way. Tracked; signature not required.
Store unopened lyophilized product at 2–8°C protected from light. Once reconstituted, most peptides are stable at 2–8°C for approximately 28 days (compound-dependent).
Developed in the 1990s by Frank Ng's group at Monash (Australia). Tested clinically as AOD-9604 by Metabolic Pharmaceuticals for obesity (failed to meet primary endpoint in Phase IIb). Not FDA-approved; GRAS designation granted for cosmetic use.
All PeptideBros compounds are sold strictly as chemical reference materials for in-vitro laboratory research. They are not for human consumption.
HPLC-verified. Mass-spec confirmed. Ambient-stable transit. The paperwork other vendors hope you never ask for.